Cargando…

Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

Castration-resistant prostate cancer (CRPC) development is the foremost concern after treatment of patients with high risk with locally advanced or metastatic prostate cancer. Androgen receptor (AR) is the main driver of CRPC development, through its interaction with epigenetic modifier genes, placi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orea, María J., Angulo, Javier C., González-Corpas, Ana, Echegaray, David, Marvá, Marcos, Lobo, María V. T., Colás, Begoña, Ropero, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820886/ https://www.ncbi.nlm.nih.gov/pubmed/36614243 http://dx.doi.org/10.3390/ijms24010803

Ejemplares similares

Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth
por: Ashour, Nadia, et al.
Publicado: (2020)

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
por: Angulo, Javier C., et al.
Publicado: (2021)

Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer
por: Martínez-Martínez, Desirée, et al.
Publicado: (2021)

Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer
por: Seo, Kyung Won, et al.
Publicado: (2010)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer
por: Meisel, Alexander, et al.
Publicado: (2022)

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)

Identification of claudin-1, −3, −7 and −8 as prognostic markers in human laryngeal carcinoma
por: Zhou, Shu, et al.
Publicado: (2019)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
por: Davidson, Ben, et al.
Publicado: (2023)

Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer
por: Yun, Seok Joong, et al.
Publicado: (2017)

DNA Methylation, Histone Modifications, and Signal Transduction Pathways: A Close Relationship in Malignant Gliomas Pathophysiology
por: Alelú-Paz, Raúl, et al.
Publicado: (2012)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
por: Chang, Li-Wen, et al.
Publicado: (2021)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Expression and significance of PTEN and Claudin-3 in prostate cancer
por: Ye, Xinglong, et al.
Publicado: (2019)

Immunoexpression of Claudins -3, -4 and -7 in prostate adenocarcinomas
por: Popescu, Tudor Cristian Timotei, et al.
Publicado: (2023)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells
por: Lin, Xiao-Dan, et al.
Publicado: (2021)

The claudins
por: Lal-Nag, Madhu, et al.
Publicado: (2009)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma
por: Bartholow, Tanner L, et al.
Publicado: (2011)

Claudin Loss-of-Function Disrupts Tight Junctions and Impairs Amelogenesis
por: Bardet, Claire, et al.
Publicado: (2017)

Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer
por: Choi, Wendy W. Y., et al.
Publicado: (2022)

Prognostic Significance of Claudin 4 in Completely Resected Adenocarcinoma of the Lung
por: Chae, Min Cheol, et al.
Publicado: (2014)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer
por: Kojima, Manabu, et al.
Publicado: (2020)

Claudin-9 is a novel prognostic biomarker for endometrial cancer
por: Endo, Yuta, et al.
Publicado: (2022)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer
por: Park, Jeong Min, et al.
Publicado: (2012)

Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
por: Hong, Peng, et al.
Publicado: (2018)

Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
por: Ozyigit, Gokhan, et al.
Publicado: (2019)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
por: De Laere, Bram, et al.
Publicado: (2021)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8tv7do2sekp30jbsr7gu32320o